Leerink Partnrs Analysts Raise Earnings Estimates for Pfizer

Pfizer Inc. (NYSE:PFE) – Leerink Partnrs upped their FY2024 EPS estimates for Pfizer in a research report issued on Tuesday, October 29th. Leerink Partnrs analyst D. Risinger now anticipates that the biopharmaceutical company will post earnings of $3.10 per share for the year, up from their prior estimate of $2.88. The consensus estimate for Pfizer’s current full-year earnings is $2.67 per share. Leerink Partnrs also issued estimates for Pfizer’s FY2025 earnings at $3.12 EPS, FY2026 earnings at $3.24 EPS and FY2028 earnings at $2.82 EPS.

Other analysts have also recently issued reports about the company. UBS Group increased their target price on Pfizer from $30.00 to $31.00 and gave the stock a “neutral” rating in a research note on Wednesday, July 31st. Daiwa Capital Markets upgraded shares of Pfizer from a “neutral” rating to an “outperform” rating and raised their price objective for the stock from $28.00 to $34.00 in a report on Wednesday, August 7th. Sanford C. Bernstein assumed coverage on shares of Pfizer in a research note on Thursday, October 17th. They issued a “market perform” rating and a $32.00 target price for the company. StockNews.com raised Pfizer from a “hold” rating to a “buy” rating in a research note on Wednesday, October 9th. Finally, Barclays upped their price objective on Pfizer from $30.00 to $32.00 and gave the stock an “equal weight” rating in a research report on Wednesday, July 31st. Eight analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $33.58.

Pfizer Stock Up 0.2 %

Shares of Pfizer stock opened at $28.52 on Thursday. Pfizer has a 1 year low of $25.20 and a 1 year high of $31.54. The company has a debt-to-equity ratio of 0.65, a current ratio of 0.86 and a quick ratio of 0.60. The company has a market capitalization of $161.61 billion, a P/E ratio of 38.54, a price-to-earnings-growth ratio of 0.99 and a beta of 0.67. The business has a 50-day moving average of $29.06 and a two-hundred day moving average of $28.56.

Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, October 29th. The biopharmaceutical company reported $1.06 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.64 by $0.42. The company had revenue of $17.70 billion during the quarter, compared to analyst estimates of $14.92 billion. Pfizer had a negative net margin of 4.66% and a positive return on equity of 8.42%. The firm’s revenue was up 31.2% on a year-over-year basis. During the same quarter in the previous year, the business earned ($0.17) EPS.

Pfizer Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Monday, December 2nd. Shareholders of record on Friday, November 8th will be given a dividend of $0.42 per share. This represents a $1.68 annualized dividend and a yield of 5.89%. The ex-dividend date of this dividend is Friday, November 8th. Pfizer’s dividend payout ratio (DPR) is currently 227.03%.

Institutional Trading of Pfizer

A number of large investors have recently added to or reduced their stakes in the company. American Capital Advisory LLC grew its holdings in Pfizer by 31.2% during the third quarter. American Capital Advisory LLC now owns 2,582 shares of the biopharmaceutical company’s stock worth $75,000 after purchasing an additional 614 shares during the period. Centennial Wealth Advisory LLC boosted its stake in shares of Pfizer by 23.1% during the 3rd quarter. Centennial Wealth Advisory LLC now owns 22,128 shares of the biopharmaceutical company’s stock worth $640,000 after acquiring an additional 4,149 shares during the period. Harvest Portfolios Group Inc. increased its holdings in shares of Pfizer by 13.1% during the 3rd quarter. Harvest Portfolios Group Inc. now owns 70,900 shares of the biopharmaceutical company’s stock worth $2,052,000 after acquiring an additional 8,200 shares during the last quarter. Radnor Capital Management LLC bought a new stake in Pfizer in the 3rd quarter valued at $2,972,000. Finally, Callahan Advisors LLC lifted its holdings in Pfizer by 8.8% during the 3rd quarter. Callahan Advisors LLC now owns 419,139 shares of the biopharmaceutical company’s stock valued at $12,130,000 after purchasing an additional 33,762 shares during the last quarter. Institutional investors and hedge funds own 68.36% of the company’s stock.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.